Major depressive disorder
Conditions
Interventions
Trade Name: Cipralex
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Escitalopram
Other descriptive name: ESCITALOPRAM OXALATE
Concentration unit: mg milligram(s)
Concentration type: equa
Sponsors
Department of Psychiatry and Psychotherapy, Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID) - Diagnosis of a moderate to severe depressive episode without psychotic symptoms (ICD diagnosis F32.1-2, F33.1-2) for the patients suffering from MDD - Hamilton Depression Scale (HAM-D 17-item)=18 (depressed patients only) - Age 18 to 55 years - Willingness and competence to sign the informed consent form. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Any medical, psychiatric or neurological illness (other than depression) - Psychopharmacological treatment within 3 months prior to inclusion - Pregnancy - Any implant or stainless steel graft or any other contraindications for MRI. - Body mass index 30 (Erritzoe, Frokjaer et al. 2010) - Current or former substance abuse - Failure to comply with the study protocol or to follow the instruction of the investigating team.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the influence of depression and antidepressant treatment on intra- and extra-dimensional set-shifting as a measure of cognitive flexsibility and on brain structure and function;Secondary Objective: To investigate the relationship between brain activity and task performance;Primary end point(s): brain structure, brain activity and connectivity, task performance ;Timepoint(s) of evaluation of this end point: at each MRI scanning session | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): treatment response score;Timepoint(s) of evaluation of this end point: at screening, each MRI scanning session and final examination | — |
Countries
Austria
Contacts
Public ContactDepartment of Psychiatry
Medical University of Vienna
Outcome results
None listed